GOSS
Gossamer Bio Inc

2,565
Mkt Cap
$722.71M
Volume
2.74M
52W High
$3.60
52W Low
$0.6666
PE Ratio
-4.45
GOSS Fundamentals
Price
$3.06
Prev Close
$3.11
Open
$3.11
50D MA
$2.61
Beta
2.30
Avg. Volume
3.2M
EPS (Annual)
-$0.2499
P/B
-8.60
Rev/Employee
$791,041.38
Loading...
Loading...
News
all
press releases
Gossamer Bio (NASDAQ:GOSS) Shares Up 7.4% - Should You Buy?
Gossamer Bio (NASDAQ:GOSS) Trading 7.4% Higher - Here's Why...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Acadian Asset Management LLC Raises Position in Gossamer Bio, Inc. $GOSS
Acadian Asset Management LLC lifted its position in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 12.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·9d ago
News Placeholder
FY2025 Earnings Forecast for Gossamer Bio Issued By Wedbush
Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Stock analysts at Wedbush lowered their FY2025 EPS estimates for shares of Gossamer Bio in a report issued on Thursday, November 6th. Wedbush analyst...
MarketBeat·12d ago
News Placeholder
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial...
Business Wire·15d ago
News Placeholder
Gossamer Bio to Participate in Upcoming Investor Conferences
Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial...
Business Wire·15d ago
News Placeholder
Gossamer Bio (NASDAQ:GOSS) Issues Earnings Results, Misses Expectations By $0.02 EPS
Gossamer Bio (NASDAQ:GOSS - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by...
MarketBeat·15d ago
News Placeholder
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -10.53% and +118.76%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of +5.56% and +155.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of -12.82% and -1.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
GSK (GSK) Q2 Earnings and Revenues Beat Estimates
Glaxo (GSK) delivered earnings and revenue surprises of +9.82% and +3.25%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago

Latest GOSS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.